Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways
The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Abstract
RNA interference (RNAi) is a universal and evolutionarily conserved phenomenon of post-transcriptional gene silencing by means of sequence-specific mRNA degradation, triggered by small double-stranded RNAs. Because this mechanism can be efficiently induced in vivo by expressing target-complementary short hairpin RNA (shRNA) from non-viral and viral vectors, RNAi is attractive for functional genomics and human therapeutics. Here we systematically investigate the long-term effects of sustained high-level shRNA expression in livers of adult mice. Robust shRNA expression in all the hepatocytes after intravenous infusion was achieved with an optimized shRNA delivery vector based on duplex-DNA-containing adeno-associated virus type 8 (AAV8). An evaluation of 49 distinct AAV/shRNA vectors, unique in length and sequence and directed against six targets, showed that 36 resulted in dose-dependent liver injury, with 23 ultimately causing death. Morbidity was associated with the downregulation of liver-derived microRNAs (miRNAs), indicating possible competition of the latter with shRNAs for limiting cellular factors required for the processing of various small RNAs. In vitro and in vivo shRNA transfection studies implied that one such factor, shared by the shRNA/miRNA pathways and readily saturated, is the nuclear karyopherin exportin-5. Our findings have fundamental consequences for future RNAi-based strategies in animals and humans, because controlling intracellular shRNA expression le…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cellular toxicity can, for example, be observed in rAAV shRNA overexpression studies in which ubiquitous promoters were used that caused saturation of cellular miRNA pathways [88].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [88]
In the citing paper
“However, the relatively large size, the requirement that the transcript starts with a G or A, the sometimes too active transcription, and the sensitivity to specific cellular profiles make the human U6 promoter a less versatile promoter [88,131,132].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [88]
In the citing paper
“Consistent with this possibility, when multiple miRNAs are packaged within a single construct, they may compete for processing by the cellular miRNA biogenesis machinery, leading to reduced efficiency in individual miRNA maturation and function 44,45 .”
From rAAV-mediated Multi-miRNA Delivery Targeting MAPK Pathway Suppresses Laser-induced Choroidal Neovascularization in Mice (2026) · cites this paper as [44]
Citations
Cites
Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
The functions of animal microRNAs
Ambros, V. (2004) · Nature · doi:10.1038/nature02871 · Cited by 10,728
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
Hannon, G. J. (2002) · Nature · doi:10.1038/418244a · Cited by 3,538
Identification of tissue-specific microRNAs from mouse
Lagos-Quintana, M., Rauhut, R., Yalcin, A., Meyer, J., Lendeckel, W., & Tuschl, T. (2002) · Current Biology · doi:10.1016/s0960-9822(02)00809-6 · Cited by 3,355
Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs
Yi, R., Qin, Y., Macara, I. G., & Cullen, B. R. (2003) · Genes & Development · doi:10.1101/gad.1158803 · Cited by 3,010
Nuclear Export of MicroRNA Precursors
Lund, E., Güttinger, S., Calado, A., Dahlberg, J. E., & Kutay, U. (2004) · Science · doi:10.1126/science.1090599 · Cited by 2,714
Mechanisms of gene silencing by double-stranded RNA
Meister, G., & Tuschl, T. (2004) · Nature · doi:10.1038/nature02873 · Cited by 2,539
Modulation of Hepatitis C Virus RNA Abundance by a Liver-Specific MicroRNA
Jopling, C. L., Yi, M., Lancaster, A. M., Lemon, S. M., & Sarnow, P. (2005) · Science · doi:10.1126/science.1113329 · Cited by 2,521
Self-citationExportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs
BOHNSACK, M. T., CZAPLINSKI, K., & GÖRLICH, D. (2004) · RNA · doi:10.1261/rna.5167604 · Cited by 1,433
Cited by
Items 401–500 of 1,001
Suppression of mouse rhodopsin expression in vivo by AAV mediated siRNA delivery
Gorbatyuk, M. S., Justilien, V., Liu, J., Hauswirth, W. W., & Lewin, A. S. (2007) · Vision Research · doi:10.1016/j.visres.2006.11.026 · Cited by 66
Li, C., Xiao, P., Gray, S. J., Weinberg, M. S., & Samulski, R. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1109522108 · Cited by 66
Brunger, J. M., Zutshi, A., Willard, V. P., Gersbach, C. A., & Guilak, F. (2017) · Arthritis & Rheumatology · doi:10.1002/art.39982 · Cited by 68
“However, unlike approaches relying on RNAi, the targeted gene deletion used in this work abolishes the expression of functional gene product without the risk of toxicity associated with saturating microRNA pathways (45).”
MethodOhtsuka, M., Ogiwara, S., Miura, H., Mizutani, A., Warita, T., Sato, M., Imai, K., Hozumi, K., Sato, T., Tanaka, M., et al. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq860 · Cited by 68
Novak, M., Halbout, B., O'Connor, E. C., Rodriguez Parkitna, J., Su, T., Chai, M., Crombag, H. S., Bilbao, A., Spanagel, R., Stephens, D. N., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.2550-10.2010 · Cited by 63
“Previous use of RNAi-based approaches have raised our awareness that excessive levels of short RNAs may oversaturate exportin 5 and thus block the processing of endogenous short RNAs leading to perturbed cellular homeostasis (Grimm et al., 2006).”
BackgroundK14 mRNA reprogramming for dominant epidermolysis bullosa simplex
Wally, V., Brunner, M., Lettner, T., Wagner, M., Koller, U., Trost, A., Murauer, E. M., Hainzl, S., Hintner, H., & Bauer, J. W. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq405 · Cited by 65
de Solis, C. A., Ho, A., Holehonnur, R., & Ploski, J. E. (2016) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2016.00070 · Cited by 66
“This system also offers a potentially better alternative to RNAi mediated gene knockdown which requires the constant overexpression of an shRNA to mediate gene knockdown and in some cases has proven to be toxic when utilized in vivo (Grimm et al., 2006; McBride et al., 2008; de Solis et al., 2015).”
BackgroundAwazawa, M., Gabel, P., Tsaousidou, E., Nolte, H., Krüger, M., Schmitz, J., Ackermann, P., Brandt, C., Altmüller, J., Motameny, S., et al. (2017) · Nature Medicine · doi:10.1038/nm.4420 · Cited by 65
AAV vector-mediated in vivo reprogramming into pluripotency
Senís, E., Mosteiro, L., Wilkening, S., Wiedtke, E., Nowrouzi, A., Afzal, S., Fronza, R., Landerer, H., Abad, M., Niopek, D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05059-x · Cited by 64
Self-citationTargeting miRNA-based medicines to cystic fibrosis airway epithelial cells using nanotechnology
Cryan, S., McKiernan, P. J., Cunningham, & Greene, C. M. (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s47551 · Cited by 72
“Previous work has found that high levels of artificial RNAi substrates delivered to cells can cause cellular toxicity and may compete for endogenous RNAi machinery, leading to disruption of natural miRNA function.(39,40) Therefore, at high N/P ratios, the PEI-based nanomedicines may in essence be too effective at deli…”
BackgroundTrobridge, G. D., Wu, R. A., Beard, B. C., Chiu, S. Y., Muñoz, N. M., von Laer, D., Rossi, J. J., & Kiem, H. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007693 · Cited by 64
“Using the competitive repopulation model we describe here, we plan to test additional combinatorial vectors we have recently constructed that contain H1 Pol III and also Pol II promoters for shRNA expression which may be safer in terms of offtarget effects on endogenous microRNAs [53-55].”
MethodSingle Intramuscular Injection of AAV-shRNA Reduces DNM2 and Prevents Myotubular Myopathy in Mice
Tasfaout, H., Lionello, V. M., Kretz, C., Koebel, P., Messaddeq, N., Bitz, D., Laporte, J., & Cowling, B. S. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.008 · Cited by 67
Wang, H., Ghosh, A., Baigude, H., Yang, C.-S., Qiu, L., Xia, X., Zhou, H., Rana, T. M., & Xu, Z. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800834200 · Cited by 66
Expressing short hairpin RNAs in vivo
Snøve, O., & Rossi, J. J. (2006) · Nature Methods · doi:10.1038/nmeth927 · Cited by 68
“Perhaps not surprisingly, mice that were injected with adeno-associated virus–based vectors harboring shRNAs succumbed to toxicity elicited by high-level expression of various shRNA sequence”
BackgroundChen, C., Sun, C., Ma, H.-I., Fang, C.-C., Wu, P.-Y., Xiao, X., & Tao, M. (2008) · Molecular Therapy · doi:10.1038/mt.2008.245 · Cited by 65
Methods in mammalian cell line engineering: from random mutagenesis to sequence-specific approaches
Krämer, O., Klausing, S., & Noll, T. (2010) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-010-2798-6 · Cited by 72
Fluiter, K., Mook, O. R. F., & Baas, F. (2009) · Methods in Molecular Biology · doi:10.1007/978-1-60327-547-7_9 · Cited by 58
Hewett, J. W., Nery, F. C., Niland, B. P., Ge, P., Tan, P., Hadwiger, P., Tannous, B. A., Sah, D. W. Y., & Breakefield, X. O. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn032 · Cited by 66
“Critical considerations for clinical translation are consistency and predictability of drug levels and ability to temporally regulate drug levels, which represent significant challenges for a gene therapeutic shRNA approach (41), in contrast to an siRNA approach.”
ResultGene Silencing Mediated by Magnetic Lipospheres Tagged with Small Interfering RNA
del Pino, P., Muñoz‐Javier, A., Vlaskou, D., Rivera-Gil, P., Plank, C., & Parak, W. J. (2010) · Nano Letters · doi:10.1021/nl102485v · Cited by 62
Scholefield, J., Greenberg, L. S., Weinberg, M. S., Arbuthnot, P. B., Abdelgany, A., & Wood, M. J. A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007232 · Cited by 74
“Primary miRNA mimics have advantages as gene silencing agents since they permit tissue specific regulation and are processed efficiently to yield physiological levels of the active guide strand [29,30,31].”
BackgroundCompagno, D., Arnold, C., Morin, A., Gilbert, C., Mathieu, J. R. R., Bözec, A., Mauduit, C., Benahmed, M., & Cabon, F. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001006 · Cited by 68
“Infection of cells with lentiviral vectors expressing short hairpin RNA (shRNA), triggers a strong silencing of the target, but therapeutic applications of this approach are limited by risks linked to the stable integration of the viral genome in the host, by the difficulty to infect in vivo a large number of cells an…”
BackgroundBiomimetic RNA‐Silencing Nanocomplexes: Overcoming Multidrug Resistance in Cancer Cells
Wang, Z., Wang, Z., Liu, D., Yan, X., Wang, F., Niu, G., Yang, M., & Chen, X. S. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201309985 · Cited by 62
Grosse, S., Penaud-Budloo, M., Herrmann, A.-K., Börner, K., Fakhiri, J., Laketa, V., Krämer, C., Wiedtke, E., Gunkel, M., Ménard, L., et al. (2017) · Journal of Virology · doi:10.1128/jvi.01198-17 · Cited by 57
Self-citationsiRNA Design Principles and Off-Target Effects
Petri, S., & Meister, G. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-311-4_4 · Cited by 67
Safe, Long-term Hepatic Expression of Anti-HCV shRNA in a Nonhuman Primate Model
Suhy, D. A., Kao, S.-C., Mao, T. K., Whiteley, L. O., Denise, H., Souberbielle, B. E., Burdick, A. D., Hayes, K., Wright, J. F., Lavender, H., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.119 · Cited by 62
MicroRNAs in common diseases and potential therapeutic applications
Tsai, L. M., & Yu, D. (2009) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2009.05269.x · Cited by 68
“shown by the experiment of sustained high-level shRNA expression in livers of adult mice leading to serious hepatocellular toxicity and fatality.(63) This saturation effect was explained by the overloading of”
Backgroundde Martimprey, H., Bertrand, J., Fusco, A., Santoro, M. M., Couvreur, P., Vauthier, C., & Malvy, C. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm1094 · Cited by 61
Chemical Modification of Small Interfering RNA
Bramsen, J. B., & Kjems, J. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-037-9_5 · Cited by 61
Fan, J., Feng, Y., Zhang, R., Zhang, W., Shu, Y., Zeng, Z., Huang, S., Zhang, L., Huang, B., Wu, D., et al. (2019) · Cancer Gene Therapy · doi:10.1038/s41417-019-0113-y · Cited by 64
RNA interference (RNAi)-based therapeutics for treatment of rare neurologic diseases
Germain, N. D., Chung, W. K., & Sarmiere, P. D. (2022) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2022.101148 · Cited by 65
Börner, K., Niopek, D., Cotugno, G., Kaldenbach, M., Pankert, T., Willemsen, J., Zhang, X., Schürmann, N., Mockenhaupt, S., Serva, A., et al. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt836 · Cited by 61
Self-citationTam, L. C. S., Kiang, A., Kennan, A., Kenna, P. F., Chadderton, N., Ader, M., Palfi, A., Aherne, A., Ayuso, C., Campbell, M., et al. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn107 · Cited by 64
“In addition to the importance of possible changes at the transcriptional level, it is imperative to profile retinal miRNAs following the inoculation of rAAV-shRNAs, since it has been reported that excessive RNAi can cause lethality in mice by oversaturation of the natural endogenous RNAi/ miRNA pathway (63).”
BackgroundNot miR-ly small RNAs: Big potential for microRNAs in therapy
Love, T. M., Moffett, H. F., & Novina, C. D. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.12.1167 · Cited by 67
From Loci to Biology: Functional Genomics of Genome-Wide Association for Coronary Disease
Nurnberg, S. T., Zhang, H., Hand, N. J., Bauer, R. C., Saleheen, D., Reilly, M. P., & Rader, D. J. (2016) · Circulation Research · doi:10.1161/circresaha.115.306464 · Cited by 57
“However, the nuclear export protein, Exportin-5, which shuttles shRNA to the cytoplasm has been shown to be limiting in the biogenesis of shRNA, leading to initial limitations of this approach.(122) Several subsequent innovations have alleviated these concerns, which were partly because of saturation of the miRNA biog…”
The neuronal migration hypothesis of dyslexia: a critical evaluation 30 years on.
Guidi, L. G., Velayos‐Baeza, A., Martinez‐Garay, I., Monaco, A. P., Paracchini, S., Bishop, D. V. M., & Molnár, Z. (2018) · European Journal of Neuroscience · doi:10.1111/ejn.14149 · Cited by 59
“In the example of Dcx (Baek et al., 2014), it was shown that shRNAs can lead to a disruption in the levels of microRNAs which, in turn, can cause problems with cell migration (see also Grimm et al., 2006).”
BackgroundShielding the messenger (RNA): microRNA-based anticancer therapies
Sotillo, E., & Thomas‐Tikhonenko, A. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.04.006 · Cited by 65
“This saturation leads to a shortage of proteins required for the processing of miRNAs, such as exportin-5, resulting in high organ toxicity and, in some cases, death (Grimm et al. 2006).”
BackgroundsiRNA as a tool to improve the treatment of brain diseases: Mechanism, targets and delivery
Gomes, M. J., Martins, S., & Sarmento, B. F. C. C. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2015.03.001 · Cited by 63
A facile method for somatic, lifelong manipulation of multiple genes in the mouse liver
Wangensteen, K. J., Wilber, A. C., Keng, V. W., He, Z., Matise, I., Wangensteen, L., Carson, C. M., Chen, Y., Steer, C. J., McIvor, S. R., et al. (2008) · Hepatology · doi:10.1002/hep.22195 · Cited by 63
Martier, R., Liefhebber, J., Miniarikova, J., van der Zon, T., Snapper, J., Kolder, I., Petry, H., van Deventer, S., Evers, M., & Konstantinova, P. (2019) · Molecular Therapy: Nucleic Acids · doi:10.1016/j.omtn.2019.01.010 · Cited by 53
Discovering and validating cancer genetic dependencies: approaches and pitfalls
Lin, A., & Sheltzer, J. M. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-020-0247-7 · Cited by 64
Khodr, C. E., Becerra, A., Han, Y., & Bohn, M. C. (2014) · Brain Research · doi:10.1016/j.brainres.2014.01.010 · Cited by 61
Fakhiri, J., Schneider, M. A., Puschhof, J., Stanifer, M., Schildgen, V., Holderbach, S., Voss, Y., El Andari, J., Schildgen, O., Boulant, S., et al. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.01.003 · Cited by 56
“In this backbone, two AAV ITRs, one of which carries a mutation of the terminal resolution site, flank the expression cassettes and allow for their packaging as scAAV genomes.(88)”
BackgroundSelf-citationde Martimprey, H., Bertrand, J., Fusco, A., Santoro, M. M., Couvreur, P., Vauthier, C., & Malvy, C. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn882 · Cited by 65
“In fact, the lack of specificity is the main cause of side effects in preclinical trials (36).”
BackgroundUsing drug-excipient interactions for siRNA delivery
Bruno, K. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.09.003 · Cited by 60
“However, concerns about competition with the native micro-RNA pathway as well as interferon response of innate immunity towards longer ds RNA limit their applicability in human [10] .”
BackgroundMTP inhibition as a treatment for dyslipidaemias: time to deliver or empty promises?
Burnett, J. R., & Watts, G. F. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.2.181 · Cited by 59
“Furthermore, a recent report in mice [86] cautions that safe and effective RNA-based gene therapies depend on a thorough understanding of the endogenous molecular mechanisms involved [87].”
BackgroundCruz, P. E., Mueller, C., Cossette, T. L., Golant, A., Tang, Q., Beattie, S. G., Brantly, M., Campbell‐Thompson, M., Blomenkamp, K., Teckman, J. H., et al. (2007) · Laboratory Investigation · doi:10.1038/labinvest.3700629 · Cited by 61
siRNA-based therapeutic approaches for rheumatic diseases
Apparailly, F., & Jørgensen, C. (2012) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2012.176 · Cited by 58
On future’s doorstep: RNA interference and the pharmacopeia of tomorrow
Gewirtz, A. M. (2007) · Journal of Clinical Investigation · doi:10.1172/jci34274 · Cited by 65
Innovative developments and emerging technologies in RNA therapeutics
Halloy, F., Biscans, A., Bujold, K. E., Debacker, A. J., Hill, A. C., Lacroix, A., Luige, O., Strömberg, R., Sundström, L., Vogel, J., et al. (2022) · RNA Biology · doi:10.1080/15476286.2022.2027150 · Cited by 58
“cleotides, which can lead to non-specific toxicity [202].”
Background25 years of maturation: A systematic review of RNAi in the clinic
Corydon, I. J., Fabian-Jessing, B. K., Jakobsen, T. S., Jørgensen, A. C., Jensen, E. G., Askou, A. L., Aagaard, L., & Corydon, T. J. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.07.018 · Cited by 63
Off-target effects associated with long dsRNAs in Drosophila RNAi screens
Moffat, J., Reiling, J. H., & Sabatini, D. M. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.02.009 · Cited by 57
Improving siRNA Bio-Distribution and Minimizing Side Effects
Scaggiante, B., Dapas, B., Farra, R., Grassi, M., Pozzato, G., Giansante, C., & Grassi, G. (2011) · Current Drug Metabolism · doi:10.2174/138920011794520017 · Cited by 61
“Finally, viral vectors-based delivery systems [25] have been shown in some cases to perturb the processing of native RNAi [109] and thus their use may bring to confounding results.”
BackgroundHigh-Capacity Adenoviral Vector-Mediated Reduction of Huntingtin Aggregate Load In Vitro and In Vivo
Huang, B., Schiefer, J., Sass, C., Landwehrmeyer, G. B., Kosinski, C. M., & Kochanek, S. (2007) · Human Gene Therapy · doi:10.1089/hum.2006.160 · Cited by 56
Tews, B., Schönig, K., Arzt, M. E., Clementi, S., Rioult-Pedotti, M.-S., Zemmar, A., Berger, S. M., Schneider, M., Enkel, T., Weinmann, O., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217665110 · Cited by 56
“To ensure that overexpression of the transgenic miRNA had no influence on the overall miRNA-processing machinery (19), we compared the expression profiles of 359 abundantly expressed miRNA sequences in L2 and WT rats (Fig.”
Bish, L. T., Sleeper, M. M., Reynolds, C., Gazzara, J. A., Withnall, E., Singletary, G. E., Buchlis, G., Hui, D. J., High, K. A., Gao, G., et al. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.035 · Cited by 61
“A study described hepatotoxicity and death in mice approximately 1 month after intravenous injection of an AAV vector expressing various shRNA sequences, and it was determined that oversaturation of endogenous microRNA pathways by the exogenous shRNA was responsible (Grimm et al., 2006).”
InfluentialRNA Interference: A Tool for Querying Nervous System Function and an Emerging Therapy
Davidson, B. L., & Boudreau, R. L. (2007) · Neuron · doi:10.1016/j.neuron.2007.02.020 · Cited by 62
Vlassov, A. V., Korba, B. E., Farrar, K., Mukerjee, S., Seyhan, A. A., Ilves, H., Kaspar, R. L., Leake, D., Kazakov, S. A., & Johnston, B. H. (2007) · Oligonucleotides · doi:10.1089/oli.2006.0069 · Cited by 63
“After a report of cytotoxic effects when shRNA was delivered to tumor cells by lentiviral vectors (Fish and Kruithof, 2004), the long-term effects of sustained high-level shRNA expression (from adeno-associated virus serotype 8, AAV8) in livers of adult mice were investigated (Grimm et al., 2006).”
Gene suppression approaches to neurodegeneration
Ghosh, R., & Tabrizi, S. J. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0307-1 · Cited by 61
“gated by selecting promoters for only modest expression of shRNAs, or by the co-expression of recombinant exportin-5 [64, 66].”
Putzbach, W., Gao, Q. Q., Patel, M., van Dongen, S., Haluck-Kangas, A., Sarshad, A. A., Bartom, E. T., Kim, K. A., Scholtens, D. M., Hafner, M., et al. (2017) · eLife · doi:10.7554/elife.29702 · Cited by 59
“, 2006; Petri and Meister, 2013), poisoning/saturating of the RISC (Grimm et al., 2006), or evocation of an IFN response (Marques and Williams, 2005).”
BackgroundGorbatyuk, O. S., Li, S., Nguyen, F. N., Manfredsson, F. P., Kondrikova, G., Sullivan, L. F., Meyers, C., Chen, W., Mandel, R. J., & Muzyczka, N. (2010) · Molecular Therapy · doi:10.1038/mt.2010.137 · Cited by 67
Therapeutic RNA interference for neurodegenerative diseases: From promise to progress
Gonzalez‐Alegre, P. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.01.003 · Cited by 61
Hepatitis B Virus Infection, MicroRNAs and Liver Disease
Sarkar, N., & Chakravarty, R. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160817746 · Cited by 60
“The most important concern, as of now, in this respect, is the delivery of the miRNAs, as delivery by an inappropriate procedure would be highly cyto-toxic [88].”
BackgroundSaayman, S. M., Barichievy, S., Capovilla, A., Morris, K. V., Arbuthnot, P. B., & Weinberg, M. S. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002602 · Cited by 60
“Secondly, and more importantly, the use of multiple highly active RNA Pol III promoters can potentially flood the cell with shRNAs and abrogate the natural microRNA biogenesis pathway, leading to unwanted toxicities [37–39].”
BackgroundFreeley, M., & Long, A. (2013) · Biochemical Journal · doi:10.1042/bj20130950 · Cited by 59
Lim, D.-H., Oh, C.-T., Lee, L., Hong, J.-S., Noh, S.-H., Hwang, S., Kim, S., Han, S.-J., & Lee, Y. S. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.08.034 · Cited by 54
“However, it has been reported that overloading the endogenous RNAi machinery may be detrimental, even lethal [36].”
BackgroundGene therapy to treat cardiac arrhythmias
Bongianino, R., & Priori, S. G. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.61 · Cited by 57
Synthetic SiRNA Delivery: Progress and Prospects
Roberts, T. C., Ezzat, K., Andaloussi, S. E., & Weinberg, M. S. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-3112-5_23 · Cited by 59
Allele-specific RNAi Mitigates Phenotypic Progression in a Transgenic Model of Alzheimer's Disease
Rodríguez-Lebrón, E., Gouvion, C. M., Moore, S. A., Davidson, B. L., & Paulson, H. L. (2009) · Molecular Therapy · doi:10.1038/mt.2009.123 · Cited by 58
Preclinical In Vivo Evaluation of the Safety of a Multi-shRNA-based Gene Therapy Against HIV-1
Centlivre, M., Legrand, N., Klamer, S., Liu, Y. P., Eije, K. J. V., Bohne, M., Rijnstra, E. S.-V., Weijer, K., Blom, B., Voermans, C., et al. (2013) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2013.48 · Cited by 52
Drug Delivery Systems for the Treatment of Ischemic Stroke
Rhim, T., Lee, D. Y., & Lee, M. (2013) · Pharmaceutical Research · doi:10.1007/s11095-012-0959-2 · Cited by 57
miRNA genetic alterations in human cancers
Giannakakis, A., Coukos, G., Hatzigeorgiou, A. G., Sandaltzopoulos, R., & Zhang, L. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.9.1375 · Cited by 57
“Several groups reported that introducing siRNAs into [134] or expressing shRNAs [135] in mammalian cells can interfere with the maturation process of endogenous miRNAs.”
BackgroundXiong, K.-C., Wang, J., Li, J., Deng, Y.-Q., Po, P., Fan, H., & Liu, Y. (2016) · Journal of Insect Physiology · doi:10.1016/j.jinsphys.2016.07.003 · Cited by 56
Ananta, J. S., Paulmurugan, R., & Massoud, T. F. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00388 · Cited by 53
Toxicity in mice expressing short hairpin RNAs gives new insight into RNAi
Snøve, O., & Rossi, J. J. (2006) · Genome biology · doi:10.1186/gb-2006-7-8-231 · Cited by 62
“[1], as overexpression of this protein improved silencing of the target gene, suggesting that Exportin-5 is a ratelimiting component of the miRNA pathway.”
InfluentialDeveloping microRNA Therapeutics: Approaching the Unique Complexities
Jackson, A. L., & Levin, A. A. (2012) · Nucleic Acid Therapeutics · doi:10.1089/nat.2012.0356 · Cited by 52
“Whether exogenous microRNA mimetics can be delivered at concentrations that achieve those resulting from shRNA overexpression (Grimm et al., 2006) has yet to be established, but these results suggest the nature of the effects of RISC saturation and other micro-RNA processing activities that could be expected in the ex…”
InfluentialAAV-mediated knockdown of Peripherin-2 in vivo using miRNA-based hairpins
Georgiadis, A., Tschernutter, M., Bainbridge, J. W., Robbie, S. J., McIntosh, J., Nathwani, A. C., Smith, A. J., & Ali, R. R. (2009) · Gene Therapy · doi:10.1038/gt.2009.162 · Cited by 58
Dalzell, J. J., McMaster, S., Johnston, M. J. G., Kerr, R., Fleming, C. C., & Maule, A. G. (2009) · International Journal for Parasitology · doi:10.1016/j.ijpara.2009.05.006 · Cited by 53
Askou, A. L., Aagaard, L., Kostic, C., Arsenijevic, Y., Hollensen, A. K., Bek, T., Jensen, T. G., Mikkelsen, J. G., & Corydon, T. J. (2015) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2014.64 · Cited by 52
Bockamp, E., Sprengel, R., Eshkind, L. G., Lehmann, T. J., Braun, J. M., Emmrich, F., & Hengstler, J. G. (2008) · Regenerative Medicine · doi:10.2217/17460751.3.2.217 · Cited by 61
Involvement of MicroRNAs in Dioxin-Induced Liver Damage in the Mouse
Yoshioka, W., Higashiyama, W., & Tohyama, C. (2011) · Toxicological Sciences · doi:10.1093/toxsci/kfr130 · Cited by 53
“This estimation suggests that most cellular pathways are potentially regulated by miRNAs, which is supported by the increasing list of cellular processes regulated by miRNAs, including insulin secretion, fat storage, apoptosis, cell growth, and tumorigenesis (Gaur et al., 2007; Grimm et al., 2006; Tsuchiya et al., 200…”
BackgroundNarvaiza, I., Aparicio, O., Vera, M., Razquin, N., Bortolanza, S., Prìeto, J., & Fortes, P. (2006) · Journal of Virology · doi:10.1128/jvi.01205-06 · Cited by 53
“Thus, overexpression of shRNAs can saturate Exp-5 in tissue culture cells and in vivo (15, 58).”
BackgroundGene therapy in animal models of autosomal dominant retinitis pigmentosa.
Rossmiller, B. P., Mao, H., & Lewin, A. S. (2012) · PubMed Central · Cited by 70
MicroRNAs Regulated by Adiponectin as Novel Targets for Controlling Adipose Tissue Inflammation
Ge, Q., Gérard, J., Noël, L., Scroyen, I., & Brichard, S. M. (2012) · Endocrinology · doi:10.1210/en.2012-1623 · Cited by 52
“2) and because of potential oversaturation of endogenous small RNA pathways (22).”
BackgroundPEI protected aptamer molecular probes for contrast-enhanced in vivo cancer imaging
Gong, P., Shi, B., Zheng, M., Bi, W., Zhang, P., Hu, D., Gao, D., Sheng, Z., Zheng, C., Ma, Y., et al. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.07.011 · Cited by 52
“Previous investigations have proved that exogenous DNA can be protect from nucleolytic degradation and delivered efficiently in vivo by a number of vectors such as polycation [28], liposomes [29,30], chitosan [31], peptides [32], dendrimer [33], quantum dots [34] and virus-based vectors [35].”
BackgroundSilvestri, P., Russo, C. D., Rigattieri, S., Fedele, S., Todaro, D., Ferraiuolo, G., ALTAMURA, G., & Loschiavo, P. (2009) · Recent Advances in Cardiovascular Drug Discovery (Formerly Recent Patents on Cardiovascular Drug Discovery) · doi:10.2174/157489009788452977 · Cited by 64
“The main disadvantage is represented by the risk of interfering with the production and nuclear export of other key miRs as occurred to Grimm et al. when they tried to induce in mice a sustained high level of short hairpin RNA with an adeno-associated virus as vector [ 34 ].”
BackgroundLaufer, S., & Restle, T. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208786898806 · Cited by 59
“On the other hand, besides the fact that shRNAs might interfere with the microRNA pathway [85,86], this strategy requires a gene therapy approach in the long run [87].”
BackgroundShort Hairpin RNAs for Strand-Specific Small Interfering RNA Production
Sheng, P., Flood, K. A., & Xie, M. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00940 · Cited by 56
“Due to strong transcriptional activity of Pol III, Pol III promoter-driven shRNAs can exhibit toxicity arisen from competition with endogenous miRNAs (Grimm et al., 2006).”
BackgroundDevelopment of new RNAi therapeutics.
Liu, G., Wong‐Staal, F., & Li, Q.-X. (2007) · PubMed · doi:10.14670/hh-22.211 · Cited by 59
The Therapeutic Potential of microRNAs in Nervous System Damage, Degeneration, and Repair
Hutchison, E. R., Okun, E., & Mattson, M. P. (2009) · NeuroMolecular Medicine · doi:10.1007/s12017-009-8086-x · Cited by 51
Regulation and guidance of cell behavior for tissue regeneration via the siRNA mechanism
Cheema, S. K., Chen, E., Shea, L. D., & Mathur, A. B. (2007) · Wound Repair and Regeneration · doi:10.1111/j.1524-475x.2007.00228.x · Cited by 60
Systemic cancer therapy: Evolution over the last 60 years
Dy, G. K., & Adjei, A. A. (2008) · Cancer · doi:10.1002/cncr.23651 · Cited by 65
“More recently, despite the theoretical advantages of RNA interference (RNAi) technology, reports of fatal hepatotoxicity in mice have led to safety concerns for therapeutic applications of RNAi.27 A lesson learned from this as well as from the disappointing clinical results using antisense technologies against targets…”
BackgroundDykxhoorn, D. M., & Lieberman, J. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030242 · Cited by 52
DNA-Based Nanomaterials as Drug Delivery Platforms for Increasing the Effect of Drugs in Tumors
Shishparenok, A. N., Furman, V. V., & Zhdanov, D. D. (2023) · Cancers · doi:10.3390/cancers15072151 · Cited by 52
“In addition, there are off-target interactions, toxicity depending on the sequence and chemical composition of oligonucleotides, and saturation of endogenous RNA processing pathways [231].”
BackgroundExogenous Application of dsRNA in Plant Protection: Efficiency, Safety Concerns and Risk Assessment
Vatanparast, M., Merkel, L., & Amari, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126530 · Cited by 54
“The theoretical risk of saturating the RNAi pathway at high dsRNA concentrations is a concern, though evidence in arthropods is currently lacking [106].”
BackgroundSchistosoma mansoni: Evaluation of an RNAi-based treatment targeting HGPRTase gene
Pereira, T. C., Pascoal, V., Marchesini, R., Maia, I. G., Magalhães, L. A., Zanotti‐Magalhães, E. M., & Lopes‐Cendes, Í. (2007) · Experimental Parasitology · doi:10.1016/j.exppara.2007.11.017 · Cited by 51
“Experimental use of high doses of such molecules oversaturates the system and may be lethal to the organism as it interferes with other natural biological functions (Grimm et al., 2006).”
BackgroundMicroRNAs in prostate cancer: from biomarkers to molecularly-based therapeutics
Gordanpour, A., Nam, R. K., Sugar, L., & Seth, A. K. (2012) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2012.3 · Cited by 54
Inhibition of Hepatitis C Virus Infection in Cell Culture by Small Interfering RNAs
Chevalier, C., Saulnier, A., Bénureau, Y., Fléchet, D., Delgrange, D., Colbère-Garapin, F., Wychowski, C., & Martin, A. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300186 · Cited by 51
“48 Nevertherless, controlled doses of siRNA or expression of shRNA have already been shown to be efficient and safe in several animal models of viral infection, including in a mouse model of hepatitis B virus infection, 47 a rhesus macaque model of severe acute respiratory syndrome-associated coronavirus infection, 49…”
MethodIn Vivo Delivery of Cytoplasmic RNA Virus-derived miRNAs
Langlois, R. A., Shapiro, J. S., Pham, A. M., & tenOever, B. R. (2011) · Molecular Therapy · doi:10.1038/mt.2011.244 · Cited by 52
Recent advances in RNAi-based strategies for therapy and prevention of HIV-1/AIDS
Swamy, M. N., Wu, H., & Shankar, P. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.03.005 · Cited by 56
“competing with the endogenous miRNA machinery [22].”
BackgroundInfluentialLong-term RNAi knockdown of α-synuclein in the adult rat substantia nigra without neurodegeneration
Zharikov, A., Bai, Q., De Miranda, B. R., Van Laar, A., Greenamyre, J. T., & Burton, E. A. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.01.004 · Cited by 48
Metadata
- Authors
- Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., Marion, P., Salazar, F., & Kay, M. A.
- Affiliations
- Stanford Medicine (US)
- Universitätsklinikum Aachen (DE)
- Corresponding author
- Kay, Mark A.
- Venue
- Nature
- Published
- 2006-05
- Volume
- 441
- Issue
- 7092
- Pages
- 537-541
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1971643509
- Cited by
- 1,677
- References
- 31
- Citations by year
- 2026: 27 · 2025: 32 · 2024: 49 · 2023: 35 · 2022: 57 · 2021: 36 · 2020: 45 · 2019: 54 · 2018: 54 · 2017: 60 · 2016: 75 · 2015: 94 · 2014: 92 · 2013: 121 · 2012: 121
- FWCI
- 57.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- RNA interference, shRNA, microRNA, XPO5, hepatotoxicity, liver injury, AAV8 vector, siRNA delivery, karyopherins, post-transcriptional gene silencing, mice, gene silencing therapy, dose-dependent toxicity
- MeSH terms
- Animals, Hepatitis B virus, Humans, Liver, Liver Regeneration, Mice, Transgenic, Nucleic Acid Conformation, RNA, Survival Analysis, Karyopherins, RNA Interference, MicroRNAs, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.